2.68
-0.095(-3.43%)
Currency In USD
| Previous Close | 2.77 |
| Open | 2.72 |
| Day High | 2.77 |
| Day Low | 2.61 |
| 52-Week High | 7.13 |
| 52-Week Low | 0.46 |
| Volume | 1.04M |
| Average Volume | 13.18M |
| Market Cap | 786.36M |
| PE | -4.53 |
| EPS | -0.59 |
| Moving Average 50 Days | 1.66 |
| Moving Average 200 Days | 1.48 |
| Change | -0.1 |
If you invested $1000 in ProKidney Corp. (PROK) since IPO date, it would be worth $264.59 as of July 30, 2025 at a share price of $2.675. Whereas If you bought $1000 worth of ProKidney Corp. (PROK) shares 2 years ago, it would be worth $269.11 as of July 30, 2025 at a share price of $2.675.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
GlobeNewswire Inc.
Jul 15, 2025 11:30 AM GMT
FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetesFDA also confirmed that the ongoing Phase 3 PROACT 1 study can be used for both accelerated approval and
ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
GlobeNewswire Inc.
Jul 09, 2025 11:30 AM GMT
WINSTON-SALEM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior m
ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes
GlobeNewswire Inc.
Jul 08, 2025 11:00 AM GMT
Full results from REGEN-007 are being held and will be submitted to the American Society of Nephrology 2025 Kidney Week as a late-breaking clinical trialIn Group 1 (n=24), kidney function stabilized in patients randomized to receive two rilparencel i